Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 41 of 41 matching drugs for JAK3 — including drugs targeting any of its 7 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib JAK3 Direct 2
lmb-100, tofacitinib, mesothelin expression JAK3 Direct 1
ruxolitinib JAK3 Direct 1
ruxolitinib, erlotinib JAK3 Direct 1
ruxolitinib, radiation, temozolomide JAK3 Direct 1
trametinib, ruxolitinib JAK3 Direct 1
trametinib, ruxolitinib, retifanlimab JAK3 Direct 1
baricitinib JAK3 Direct yes 0
tofacitinib JAK3 Direct yes 0
tofacitinib citrate JAK3 Direct yes 0
upadacitinib JAK3 Direct yes 0
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FYN SSL via FYN 3
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment FYN SSL via FYN 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib JAK2 SSL via JAK2 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib JAK2 SSL via JAK2 2
afatinib, dasatinib, palbociclib, everolimus, olaparib FYN SSL via FYN 1
bevacizumab, dasatinib, placebo FYN SSL via FYN 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride FYN SSL via FYN 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method FYN SSL via FYN 1
dasatinib, laboratory biomarker analysis, physiologic testing FYN SSL via FYN 1
dasatinib, mfolfox6 FYN SSL via FYN 1
dasatinib, pharmacological study FYN SSL via FYN 1
dasatinib, temozolomide, placebo, radiation therapy FYN SSL via FYN 1
entrectinib JAK2 SSL via JAK2 yes 1
inotuzumab ozogamicin, flag (fludarabine, cytarabine and g-csf), hidac (high dose cytarabine), cytarabine and mitoxantrone CD22 SSL via CD22 1
lmb-100, tofacitinib, mesothelin expression JAK2 SSL via JAK2 1
pacritinib, sirolimus, tacrolimus, allogenic hematopoietic cell transplant (allohct) JAK2 SSL via JAK2 1
ruxolitinib JAK2 SSL via JAK2 yes 1
ruxolitinib, erlotinib JAK2 SSL via JAK2 1
ruxolitinib, radiation, temozolomide JAK2 SSL via JAK2 1
trametinib, ruxolitinib JAK2 SSL via JAK2 1
trametinib, ruxolitinib, retifanlimab JAK2 SSL via JAK2 1
baricitinib JAK2 SSL via JAK2 yes 0
dasatinib FYN SSL via FYN yes 0
fedratinib JAK2 SSL via JAK2 yes 0
fedratinib hydrochloride JAK2 SSL via JAK2 yes 0
ruxolitinib phosphate JAK2 SSL via JAK2 yes 0
tofacitinib JAK2 SSL via JAK2 yes 0
tofacitinib citrate JAK2 SSL via JAK2 yes 0
upadacitinib JAK2 SSL via JAK2 yes 0
vandetanib FYN SSL via FYN yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.